The “1st Berlin Conference on IP in Life Sciences – Smart Clinical Trials” was designed to give deeper insights into the design of clinical trials with respect to ­prolonging IP life span through pediatric use data, the set-up of first-in-man studies of biologicals, legal risks and liabilities.

Biotech executives from late-stage companies shared the lessons they learned from the outcome of recent clinical trials. Furthermore, senior experts from big pharma companies were also be on hand to answer questions involving successful licensing.

Biotech and pharmaceutical company executives and advisors responsible for clinical trials, licensing and IP strategy and protection attended this high-level event, as well as advisors and executives practicing in pharmaceuticals, IP, licensing and venture capital.

Programme

 

Welcome Address

Sir Michael Anthony Arthur (KCMG)
British Ambassador to the  Federal Republic of Germany

 

Key Note Lecture

Prof. Dr. Johannes Löwer
President, Paul-Ehrlich-Institute,
Director BfArM

 

First in Man –  Preparation and Design of Clinical Trials

PD Dr. med. Matthias Großmann
Vice President and Principal Consultant Clinical Pharmacology, PAREXEL International GmbH

 

Patenting in the Pharmaceutical Field: First and Second Medical Use for Biologicals

Dr. Ute Kilger,
Patent Attorney, Vossius & Partner

 

Contractual Risk Allocation With CRO

Dr. Jan Dirk Heerma
Partner, SJ Berwin

 

Clinical Trials with the UK
National Health Syste

Prof. Dr. Richard S. Kaplan
Associate Director,
UK Clinical Research Network

 

IP Due Diligence from the Pharma Perspective

Dr. Hans Masselink
Co-Head Transactions, Novartis Pharma AG

 

Prolonging IP’s Life Span – Data Protection SPCs and the Law of Pediatric Use

Dr. Christian Kilger
Patent Attorney, Vossius & Partner

Pharma Licensing: Pitfalls and Best Practice

Dr. Markus Werner
Associate Director Licensing, Nycomed GmbH

 

Panel Discussion: Johannes Löwer, Hans-Rainer Jaenichen, Hans Masselink, Markus Werner, Matthias Großmann, Jan Dirk Heerma, Richard S. Kaplan, Tim Tasker / Presentation: Jeff Solomon (ERBI)

 

Efficient Clinical Trials – Lessons Learned

Dr. Tim Tasker, Executive Vice President Clinical Development Evotec AG

 

Closing Remarks

Dr. Hans-Rainer Jaenichen,
Partner, Vossius & Partner

 

When & where

CONTACT & INFORMATION

 

 

Uta Holmer

Dipl.-Volkswirtin

Veranstaltungsmanagement

 

 

Telefon: +49-30-264921-53

events[at]biocom.de